Impact of dexmedetomidine supplemented analgesia on postoperative delirium and long-term survival in elderly patients after cancer surgery: A multicenter, double-blinded, randomized controlled trial

Hirota Kazuyoshi0 sites0 target enrollmentAugust 13, 2020

Overview

one

Registry

who.int

Start Date

August 13, 2020

End Date

May 30, 2022

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Hirota Kazuyoshi

•1 Age older than 65 years, less than 90 years
•2 Scheduled to undergo surgery for primary solid organ cancer under general anesthesia, with an expected duration of surgery longer than 2 hours
•3 Planned to use patient\-controlled intravenous analgesia (PCIA) after surgery
•4 Provide written informed consent.

•Patients who meet any of the following criteria will be excluded.
•1 Preoperative history of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis;
•2 Preoperative radio\- or chemotherapy;
•3 Inability to communicate in the preoperative period because of coma, profound dementia or language barrier;
•4 Preoperative obstructive sleep apnea (previously diagnosed as obstructive sleep apnea, or STOP\-Bang scoring model score
•5 Brain injury or neurosurgery;
•6 Preoperative left ventricular ejection fraction \< 30%, sick sinus syndrome, severe sinus bradycardia (\< 50 beats per minute), or second\-degree or above atrioventricular block without pacemaker;
•7 Severe hepatic dysfunction (Child\-Pugh class C) or severe renal dysfunction (requirement of renal replacement therapy before surgery);
•8 ASA classification IV or above.